Molecular Dynamics Simulations of Viral Envelope Glycoproteins: Unraveling Binding Dynamics and Drug Resistance

Introduction

Viral envelope glycoproteins are the primary mediators of host cell recognition, attachment, and membrane fusion. These metastable trimers undergo extensive conformational rearrangements upon receptor engagement, transitioning from a prefusion closed state to an open, receptor-bound conformation and ultimately to a postfusion state [1, 2]. Understanding these dynamic processes at atomic resolution is essential for rational vaccine design and the development of entry inhibitors. Molecular dynamics (MD) simulations have emerged as a powerful computational tool to probe the conformational landscapes, allosteric communication pathways, and drug resistance mechanisms of viral envelope glycoproteins [3, 4]. This article reviews the application of MD simulations to study envelope glycoproteins, with a focus on binding dynamics, immune evasion, and the emergence of drug resistance mutations. While the majority of detailed mechanistic studies have been performed on human immunodeficiency virus type 1 (HIV-1) Env, the principles are broadly applicable to veterinary retroviruses such as feline immunodeficiency virus (FIV), equine infectious anemia virus (EIAV), and other enveloped viruses of veterinary importance.

Computational Methods and Force Fields

MD simulations solve Newton's equations of motion for a system of atoms over time, generating trajectories that capture the time-dependent behavior of proteins and their solvent environment [5]. The accuracy of these simulations depends critically on the force field, which defines the potential energy function. Commonly used all-atom force fields include AMBER, CHARMM, OPLS-AA, and GROMOS, each with parameter sets optimized for proteins, lipids, and carbohydrates [6]. For viral envelope glycoproteins, which are heavily glycosylated, force fields that accurately model glycans (e.g., GLYCAM for AMBER) are essential [3]. Popular MD software packages include GROMACS, AMBER, NAMD, and CHARMM, each offering different levels of parallelization and analysis tools [7].

Simulation timescales for envelope glycoproteins typically range from hundreds of nanoseconds to several microseconds, often employing multiple replicas to enhance sampling [8]. Enhanced sampling techniques such as replica exchange molecular dynamics (REMD), metadynamics, and umbrella sampling are used to explore free energy landscapes and calculate binding affinities [9]. Coarse-grained (CG) models, such as the Martini force field, enable simulations of larger systems (e.g., full viral spikes on membrane patches) over longer timescales, albeit with reduced atomic detail [10].

Conformational Dynamics of Envelope Glycoproteins

HIV-1 Env as a Model System

The HIV-1 envelope glycoprotein (Env) is a trimer of gp120-gp41 heterodimers. The gp120 subunit mediates receptor (CD4) and coreceptor (CCR5 or CXCR4) binding, while gp41 drives membrane fusion [1, 2]. MD simulations have revealed that the unliganded gp120 core exists in a structurally stable "ground state" with limited conformational flexibility [11]. Upon CD4 binding, gp120 undergoes a large conformational rearrangement: the V1/V2 and V3 loops become more mobile, the bridging sheet forms, and the coreceptor binding site is exposed [11]. This transition is accompanied by an increase in conformational entropy and a decrease in thermostability [11].

Long-range allosteric communication within gp120 has been characterized using correlation and principal component analyses of MD trajectories [7]. Network analysis identified optimal and suboptimal communication pathways connecting the CD4 binding site to distal regions, including the coreceptor binding site and the gp41 interface [7]. These pathways are sequence-sensitive, with suboptimal pathways in one viral strain becoming optimal in another, yet conserved "inter-modular hotspots" were identified that could serve as targets for immunogen design [7].

The role of N-glycans in modulating Env dynamics has been investigated using MD simulations. N-glycans on gp120 influence the tilting of the Env trimer and shield conserved epitopes from antibody recognition [3]. The glycan shield is not static; glycans sample multiple conformations, and their dynamics affect the accessibility of underlying protein surfaces [3].

Membrane Fusion and the Role of Lipids

The fusion peptide of gp41 inserts into the host cell membrane, initiating a series of conformational changes that lead to the formation of a six-helix bundle [5]. MD simulations have tracked the protein conformational motions driving HIV-1 membrane fusion, revealing that the gp41 heptad repeat regions undergo a zipper-like folding [5]. Cholesterol has been shown to mediate gp41 linear aggregation and enhance membrane curvature, facilitating fusion pore formation [4]. Simulations of the membrane-interacting region of Env have highlighted structural heterogeneity in the gp41 membrane-proximal external region (MPER) and the transmembrane domain [6].

Env-Matrix Interactions and Virion Assembly

In the context of intact virions, MD simulations combined with cryo-electron tomography have resolved the interaction between the Env cytoplasmic tail (Env-CT) and the matrix (MA) domain of Gag [12]. The conserved Kennedy sequence motif in Env-CT forms a key linkage with MA trimers, and this interaction is modulated by Gag maturation [12]. These simulations provide a structural basis for the low copy number of Env on virions and its clustering during fusion.

Predicting Drug Resistance Mutations

MD simulations are instrumental in understanding how mutations distant from the active site or antibody epitope confer drug resistance. For HIV-1 Env, resistance to entry inhibitors (e.g., maraviroc, enfuvirtide) and broadly neutralizing antibodies often involves allosteric mechanisms [7, 10]. Mutations in gp120 that alter the dynamics of the V3 loop can switch coreceptor usage from CCR5 to CXCR4, conferring resistance to CCR5 antagonists [10]. MD simulations have shown that these mutations increase the positive charge of V3 and stabilize the CXCR4-bound conformation [10].

Protease inhibitor (PI) resistance has been linked to co-evolving mutations in Env [10]. Under PI selection pressure, Env mutations increase the number and length of N-glycosylation sites in V1/V2 and V5, enhancing immune evasion [10]. In gp41, the S534A mutation forms a hydrogen bond with L602 in the disulfide loop region, potentially affecting gp120-gp41 association and promoting cell-to-cell transmission [10].

Graph machine learning combined with MD simulations has been used to classify HIV neutralization phenotypes based on gp120 sequence variation and structural dynamics [13]. This approach identified local regions of high flexibility, particularly in the second structural elements, that correlate with neutralization resistance [13].

Case Studies in Veterinary Virology

Although the provided literature focuses on HIV-1, the methodologies are directly transferable to veterinary viruses. For example, the envelope glycoprotein of feline immunodeficiency virus (FIV) (gp95/gp36) shares structural homology with HIV-1 Env. MD simulations of FIV Env could elucidate the conformational changes upon CD134 and CXCR4 binding, and predict mutations that confer resistance to neutralizing antibodies. Similarly, the hemagglutinin (HA) of avian influenza virus undergoes pH-dependent conformational changes that can be studied using MD simulations to understand host range and drug resistance (e.g., oseltamivir resistance mutations in neuraminidase, though not envelope glycoproteins, are also amenable to MD). The rabies virus glycoprotein (G) mediates pH-dependent membrane fusion, and MD simulations could reveal how mutations in the fusion loop affect neurotropism and vaccine efficacy. For a broader discussion of these applications, readers are directed to the existing article on Molecular Dynamics Simulations of Viral Envelope Proteins: Insights into Host Recognition and Drug Design.

Workflow of MD Simulations for Envelope Glycoproteins

The following Mermaid diagram illustrates a typical workflow for MD simulations of viral envelope glycoproteins, from structure preparation to analysis of drug resistance.

flowchart TD
    A[Obtain 3D structure: X-ray, Cryo-EM, or Homology Model], > B[Prepare system: add glycans, ions, water, membrane]
    B, > C[Energy minimization and equilibration]
    C, > D[Production MD simulation: NPT ensemble, multiple replicas]
    D, > E[Trajectory analysis: RMSD, RMSF, PCA, DCCM]
    E, > F[Free energy calculations: MM-PBSA, metadynamics]
    F, > G[Identify key conformational states and allosteric pathways]
    G, > H[Mutate residues in silico and simulate mutant]
    H, > I[Compare dynamics: wild-type vs mutant]
    I, > J[Predict resistance mutations and guide drug/vaccine design]

Table: Selected MD Studies of HIV-1 Envelope Glycoproteins

Implications for Rational Vaccine Design and Antiviral Development

MD simulations provide atomic-level insights into the dynamic epitopes targeted by neutralizing antibodies. By mapping the conformational ensembles of envelope glycoproteins, researchers can identify metastable states that expose conserved, functionally important regions [1, 8]. These states can be stabilized through structure-based design of immunogens, as exemplified by the development of stabilized HIV-1 Env trimers (e.g., SOSIP) that mimic the prefusion conformation. MD simulations have been used to optimize these designs by testing mutations that reduce conformational flexibility and improve thermostability [8].

For drug resistance, MD simulations can predict the impact of mutations on drug binding affinity and protein dynamics before experimental validation. This is particularly valuable for veterinary viruses where high-throughput resistance testing may be limited. The combination of MD with machine learning, as demonstrated for HIV-1 neutralization phenotypes [13], offers a pathway to rapidly assess the resistance potential of emerging viral strains.

Conclusion

Molecular dynamics simulations have become indispensable for unraveling the complex conformational dynamics of viral envelope glycoproteins. By providing atomic-resolution trajectories of receptor binding, membrane fusion, and allosteric communication, MD simulations enable the prediction of drug resistance mutations and guide the rational design of vaccines and entry inhibitors. While the majority of detailed studies have focused on HIV-1, the methodologies are directly applicable to veterinary viruses such as FIV, EIAV, influenza, and rabies. Continued advances in force fields, enhanced sampling techniques, and integration with cryo-electron microscopy will further expand the utility of MD simulations in veterinary virology and computational biology.

References

[1] Cao Y, Im W. Conformational variability of HIV-1 Env trimer and viral vulnerability. Elife. 2026. URL: https://pubmed.ncbi.nlm.nih.gov/42360802/

[2] Majumder A, Dutta M, Cherek L, et al. Structure and Dynamics of the HIV-1 Envelope Protein on the Virion Envelope. bioRxiv. 2026. URL: https://pubmed.ncbi.nlm.nih.gov/42239368/

[3] Shehata M, Casalino L, Duquette M, et al. N-Glycans modulate tilting of HIV-1 envelope glycoprotein. Nat Commun. 2026. URL: https://pubmed.ncbi.nlm.nih.gov/41986331/

[4] Zhao J, Jiang Y, Zhao L, et al. Cholesterol Mediates Gp41 Linear Aggregation and Enhanced Membrane Curvature during HIV-1 Infection. J Phys Chem B. 2026. URL: https://pubmed.ncbi.nlm.nih.gov/41701904/

[5] Unarta IC, Crotzer S, Gnanakaran S. Tracking the protein conformational motions driving HIV-1 membrane fusion. Sci Rep. 2026. URL: https://pubmed.ncbi.nlm.nih.gov/41495110/

[6] Majumder A, Voth GA. Structural Heterogeneity of the Membrane-Interacting Region of the HIV-1 Envelope Glycoprotein. J Am Chem Soc. 2025. URL: https://pubmed.ncbi.nlm.nih.gov/41277144/

[7] Sethi A, Tian J, Derdeyn C, et al. A Mechanistic Understanding of Allosteric Immune Escape Pathways in the HIV-1 Envelope Glycoprotein. PLoS Comput Biol. 2013. URL: https://www.semanticscholar.org/paper/42e6cdf4d51c69d2d465c1f8417cd694ffa418bd

[8] Sauve S, Lu M, Moradi M. Atomic-level characterization of HIV-1 envelope glycoprotein conformational states using molecular dynamics simulations. Biophysical Journal. 2024. URL: https://www.semanticscholar.org/paper/4acee71a4943391c57270a6de43a7a148ab8c51a

[9] Serra PA, Martins A, Taveira N, et al. Structural elucidation and molecular dynamics study targeting the viral surface glycoproteins against HIV-2 infection. Annals Medicus. 2019. URL: https://www.semanticscholar.org/paper/81e097106d87dea439b55d4db9cfbd53eb2156f3

[10] Maphumulo NF, Gordon M. HIV-1 envelope facilitates the development of protease inhibitor resistance through acquiring mutations associated with viral entry and immune escape. Front Microbiol. 2024. URL: https://www.semanticscholar.org/paper/ad73452c7b637e191850748809f7c1b0bccc60bb

[11] Li Y, Deng L, Liang J, et al. Molecular dynamics simulations reveal distinct differences in conformational dynamics and thermodynamics between the unliganded and CD4-bound states of HIV-1 gp120. Phys Chem Chem Phys. 2020. URL: https://www.semanticscholar.org/paper/614c7d149536e4a97c44e4060aaeeee8dee1f98c

[12] Croft JT, Do HN, Leaman D, et al. Reconstructing a Missing Link of HIV-1 Assembly: HIV-1 Envelope-Matrix Interactions in a Native Viral Context. bioRxiv. 2026. URL: https://www.semanticscholar.org/paper/0bc9f4110a30e3bb02a856bd14ff5859af35564e

[13] Li Y, Guo YC, Cheng H, et al. Deciphering gp120 sequence variation and structural dynamics in HIV neutralization phenotype by molecular dynamics simulations and graph machine learning. Proteins: Structure, Function, and Bioinformatics. 2022. URL: https://www.semanticscholar.org/paper/782fc95e2ec3cabc4d51b0092a5f44e49f8a4afa

[14] Quijada-Freire A, Santiago C, García-Cuesta EM, et al. HIV-1 envelope glycoprotein modulates CXCR4 clustering and dynamics on the T cell membrane. bioRxiv. 2026. URL: https://www.semanticscholar.org/paper/192fab4cc1d607853c220b9a79fff1165a813dae *** Disclaimer: This article is for educational and informational purposes only. It is not intended to substitute for professional veterinary advice, diagnosis, treatment, or regulatory guidance. Always consult a licensed veterinarian or qualified specialist regarding animal health, disease diagnosis, and therapeutic decisions.